Kiniksa Pharmaceuticals International, plc $KNSA Stock Holdings Reduced by Peregrine Capital Management LLC

Peregrine Capital Management LLC cut its position in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) by 25.7% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 214,364 shares of the company’s stock after selling 74,272 shares during the period. Peregrine Capital Management LLC owned 0.29% of Kiniksa Pharmaceuticals International worth $8,324,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in KNSA. Arrowstreet Capital Limited Partnership acquired a new position in Kiniksa Pharmaceuticals International in the second quarter worth approximately $20,349,000. Qube Research & Technologies Ltd grew its position in Kiniksa Pharmaceuticals International by 277.8% in the second quarter. Qube Research & Technologies Ltd now owns 888,364 shares of the company’s stock worth $24,581,000 after acquiring an additional 653,236 shares in the last quarter. Rubric Capital Management LP grew its position in Kiniksa Pharmaceuticals International by 15.6% in the second quarter. Rubric Capital Management LP now owns 3,909,806 shares of the company’s stock worth $108,184,000 after acquiring an additional 526,567 shares in the last quarter. Cubist Systematic Strategies LLC increased its stake in shares of Kiniksa Pharmaceuticals International by 213.2% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 657,475 shares of the company’s stock worth $18,192,000 after purchasing an additional 447,536 shares during the last quarter. Finally, Squarepoint Ops LLC raised its holdings in shares of Kiniksa Pharmaceuticals International by 186.2% during the 2nd quarter. Squarepoint Ops LLC now owns 416,572 shares of the company’s stock valued at $11,527,000 after purchasing an additional 271,005 shares in the last quarter. 53.95% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages recently issued reports on KNSA. Weiss Ratings reiterated a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a report on Wednesday, October 8th. Zacks Research cut Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “hold” rating in a research report on Monday, October 6th. Wells Fargo & Company upped their price target on Kiniksa Pharmaceuticals International from $42.00 to $45.00 and gave the stock an “overweight” rating in a research note on Thursday, September 25th. Citigroup increased their price objective on Kiniksa Pharmaceuticals International from $45.00 to $50.00 and gave the company a “buy” rating in a report on Friday, October 17th. Finally, The Goldman Sachs Group raised their price objective on Kiniksa Pharmaceuticals International from $45.00 to $55.00 and gave the company a “buy” rating in a research note on Wednesday, October 29th. Six analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $52.00.

Kiniksa Pharmaceuticals International Price Performance

Kiniksa Pharmaceuticals International stock opened at $42.67 on Friday. Kiniksa Pharmaceuticals International, plc has a fifty-two week low of $17.82 and a fifty-two week high of $44.42. The firm has a fifty day moving average price of $41.26 and a two-hundred day moving average price of $36.31. The firm has a market cap of $3.23 billion, a price-to-earnings ratio of 94.82 and a beta of 0.04.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last posted its quarterly earnings data on Tuesday, October 28th. The company reported $0.23 EPS for the quarter, missing analysts’ consensus estimates of $0.31 by ($0.08). Kiniksa Pharmaceuticals International had a return on equity of 7.46% and a net margin of 6.01%.The business had revenue of $180.86 million during the quarter, compared to the consensus estimate of $166.64 million. During the same quarter in the previous year, the firm posted ($0.18) earnings per share. The company’s revenue for the quarter was up 61.2% on a year-over-year basis. As a group, sell-side analysts expect that Kiniksa Pharmaceuticals International, plc will post -0.55 earnings per share for the current year.

Insider Buying and Selling

In other news, insider John F. Paolini sold 82,542 shares of the company’s stock in a transaction that occurred on Friday, October 31st. The stock was sold at an average price of $37.14, for a total transaction of $3,065,609.88. Following the completion of the transaction, the insider directly owned 61,324 shares in the company, valued at $2,277,573.36. The trade was a 57.37% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Barry D. Quart sold 20,129 shares of the firm’s stock in a transaction on Monday, December 15th. The stock was sold at an average price of $41.51, for a total transaction of $835,554.79. Following the completion of the sale, the director owned 12,546 shares in the company, valued at approximately $520,784.46. The trade was a 61.60% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 523,057 shares of company stock worth $20,475,192. 53.48% of the stock is currently owned by company insiders.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.